Wednesday, November 30, 2022

November 30, 2022 at 10:16PM FDA Approves First Fecal Microbiota Product

FDA approves the first fecal microbiota product, Rebyota. Rebyota is approved for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older. It is for used after an individual has completed antibiotic treatment for recurrent CDI.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/bMCU2OF

November 30, 2022 at 08:12PM Biologics Electronic Reading Room (eFOI)

The Biologics eFOI Reading Room provides access to documents posted throughout the "Vaccines, Blood & Biologics" and other sections related to the Center for Biologics Evaluation and Research on the FDA.gov Web site.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/kCzdXce

November 29, 2022 at 09:40PM COVID-19 Vaccines

FDA has rigorous scientific and regulatory processes in place to facilitate development and ensure the safety, effectiveness and quality of COVID-19 vaccines.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/RvpDITl

November 29, 2022 at 02:28PM Antimicrobial Resistance Information from FDA

Antimicrobial resistance (AMR)—the ability of a microorganism (bacteria, virus, fungi, parasite) to resist the effects of a drug—is a serious, complex and costly public health problem. Learn what FDA is doing to address AMR.

via Whats New Vaccines Blood Biologics RSS Feed http://www.fda.gov/emergency-preparedness-and-response/mcm-issues/antimicrobial-resistance-information-fda

Monday, November 28, 2022

November 28, 2022 at 08:02PM KINRIX

Changes to your package insert to the Dosage and Administration section regarding visual inspection by the user for cracked vials or syringes prior to administration of the vaccine and non-use of product should those conditions exist.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/OM1C20P

November 25, 2022 at 10:44PM Recently Issued Guidance Documents

This page lists Recently Issued CBER and Cross-Center Guidance Documents.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/SlUEV1b

Friday, November 25, 2022

November 25, 2022 at 10:40PM Enforcement Policy Regarding Investigational New Drug Requirements for Use of Fecal Microbiota for Transplantation to Treat Clostridium difficile Infection Not Responsive to Standard Therapies

Enforcement Policy Regarding Investigational New Drug Requirements for Use of Fecal Microbiota for Transplantation to Treat Clostridium difficile Infection Not Responsive to Standard Therapies Draft Guidance for Industry, CBER, Biologics

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/Zt8nIOs

November 25, 2022 at 07:18PM FDA CBER OTAT Patient-Focused Drug Development Listening Meeting — Patient Perspectives on Gene Therapy Products - 11/15/2022

The FDA’s Center for Biologics Evaluation and Research (CBER) Office of Tissues and Advanced Therapies (OTAT) is hosting a virtual patient-focused drug development listening meeting to better understand patient perspectives on gene therapy products, including cell-mediated gene therapy.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/uSLMoOP

November 25, 2022 at 04:23PM Section 8100: Communication

This is the CBER SOPP Section 8100: Communication main page.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/5SI7Gjq

Tuesday, November 22, 2022

November 22, 2022 at 10:16PM Approved Cellular and Gene Therapy Products

Listing of licensed and approved products from the Office of Tissues and Advanced Therapies (OTAT).

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/qbas52D

November 22, 2022 at 05:12PM FDA Patient Listening Sessions

Patient Listening Sessions led by FDA’s Office of Patient Affairs provide an opportunity for medical product Centers to engage with patients, caregivers, and advocates about their experiences and perspectives.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/vshTYjR

November 21, 2022 at 07:33PM Oversight of Clinical Investigations — A Risk-Based Approach to Monitoring

Guidance for Industry - Oversight of Clinical Investigations — A Risk-Based Approach to Monitoring, Procedural

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/S9smWiF

Friday, November 18, 2022

November 18, 2022 at 05:21PM Roster of the Cellular, Tissue and Gene Therapies Advisory Committee

This is the Roster of the Cellular, Tissue and Gene Therapies Advisory Committee.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/OL31oBS

November 18, 2022 at 05:20PM Roster of the Blood Products Advisory Committee

This is the Roster of the Blood Products Advisory Committee (BPAC).

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/pA16BH2

November 18, 2022 at 04:38PM Studying Multiple Versions of a Cellular or Gene Therapy Product in an Early-Phase Clinical Trial

This is the guidance Studying Multiple Versions of a Cellular or Gene Therapy Product in an Early-Phase Clinical Trial

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/g8ujrC7

Wednesday, November 16, 2022

November 16, 2022 at 07:42PM Jobs at the Center for Biologics Evaluation and Research (CBER)

CBER has unique opportunities for individuals with backgrounds in science or administration to fill positions involved in the regulation and research of blood, vaccines and therapeutics.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/8CJ7THV

Tuesday, November 15, 2022

November 15, 2022 at 08:43PM Drugs@FDA Data Files

Drugs@FDA Downloadable Data File in ZIP format, Data Definitions, and Entity Relationship Diagram (ERD)

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/GDxymKg

November 15, 2022 at 06:52PM CDER Scientific Review Documents Supporting Emergency Use Authorizations for Drug and Biological Therapeutic Products | COVID-19

CDER Scientific Reviews Supporting EUA for Therapeutic Products

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/FpTQVLE

Monday, November 14, 2022

November 14, 2022 at 10:24PM INFANRIX

Product approval information for Diphtheria Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed also known as Infanrix.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/80Yc2Rq

November 14, 2022 at 09:57PM Section 8400: Marketing Applications

This is the SOPP Section 8400: Marketing Applications main page.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/uQ2PZtO

November 14, 2022 at 07:26PM Pfizer-BioNTech COVID-19 Vaccines

Information about the Comirnaty, Pfizer-BioNTech COVID-19 Vaccine, and Pfizer-BioNTech COVID-19 Vaccine, Bivalent. Updated COVID-19 vaccine boosters are now FDA-authorized.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/Vins06F

Thursday, November 10, 2022

November 10, 2022 at 05:51PM Vaccines, Blood & Biologics

From blood to vaccines, FDA protects and advances the public health by ensuring that biological products are safe, effective, and available to those who need them. Read these Consumer Updates to learn more.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/otOH9Wq

Monday, November 7, 2022

November 07, 2022 at 10:10PM Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate)

List of Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate) products

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/LVywWik

November 07, 2022 at 03:54PM Consumer Updates

Science-based health and safety information you can trust.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/6QEyVkX

Friday, November 4, 2022

November 04, 2022 at 04:09PM Complete List of Donor Screening Assays for Infectious Agents and HIV Diagnostic Assays

Links to the different types of Donor Screening Assays. A table for each assay is provided with detailed information such as tradename, infectious agent, format, specimen, use, manufacturer, approval date, and STN.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/07u5XcZ

Thursday, November 3, 2022

November 03, 2022 at 05:08PM Fluzone Quadrivalent, Fluzone High-Dose Quadrivalent, Fluzone, Intradermal Quadrivalent, Fluzone Quadrivalent Southern Hemisphere

For active immunization of persons 6 months of age and older for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/RIOzpWv

November 03, 2022 at 03:41PM Expanded Access (Compassionate Use) Submission Data

Expanded Access (Compassionate Use) Submission Data

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/Eay1f6C

November 02, 2022 at 08:21PM Pfizer-BioNTech COVID-19 Vaccines

Information about the Comirnaty, Pfizer-BioNTech COVID-19 Vaccine, and Pfizer-BioNTech COVID-19 Vaccine, Bivalent. Updated COVID-19 vaccine boosters are now FDA-authorized.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/8Nrfetu

Wednesday, November 2, 2022

November 02, 2022 at 11:11PM Biologics Electronic Reading Room (eFOI)

The Biologics eFOI Reading Room provides access to documents posted throughout the "Vaccines, Blood & Biologics" and other sections related to the Center for Biologics Evaluation and Research on the FDA.gov Web site.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/nN7Hjbe

November 02, 2022 at 11:08PM DG Gel Card 125445, 125449, 125450 - 125457

Product approval information is for:
•DG Gel 8 AB (x4) card is for the determination of human A and B antigen on the surface of red blood cells in four separate blood samples. For use with the DG Gel System. For in vitro diagnostic use.
•DG Gel 8 A/B/D card is for the determination of human A, B and D antigens on the surface of red blood cells in two separate blood samples. For use with the DG Gel System. For in vitro diagnostic use.
•DG Gel 8 ABO/Rh + Kell card is for the determination of ABO forward and reverse grouping, and D and Kell antigens on the surface of red blood cells in human blood samples. For use with the DG Gel System. For in vitro diagnostic use.
•DG Gel 8 Rh Pheno card is for the determination of human C, E, c, and e antigens on the surface of red blood cells in two separate blood samples. For use with the DG Gel System. For in vitro diagnostic use.
•DG Gel 8 T/S Mono card is for the determination of human A, B and D antigens on the surface of red blood cells, and for Indirect Antiglobulin Test in human blood samples. This assay does not contain antibodies to complement components. For use with the DG Gel System. For in vitro diagnostic use.
•DG Gel 8 Anti-IgG (Rabbit) card is for the Direct and Indirect Antiglobulin Test of human blood samples. This test does not contain antibodies to complement components.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/NKpZGHO

November 02, 2022 at 08:38PM Biologics PREA Reviews and Labeling Changes

PREA Labeling Changes, Medical, Statistical, and Clinical Pharmacology Reviews of Pediatric Studies Conducted under Section 505B of the Federal Food, Drug, and Cosmetic Act (the Act), as amended by the FDA Amendments Act of 2007 (FDAAA). These assessments are for CBER regulated drugs approved under section 505 of the Act and biological drugs licensed under section 351 of the Public Health Service Act.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/7aX82d1

November 02, 2022 at 07:58PM Boostrix

Boostrix is a product approval indicated for Booster immunization against tetanus, diphtheria and pertussis as a single dose in individuals 10 years of age and older

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/rpfFX7C